This is an investigational study. Ponatinib is FDA approved and commercially available for the treatment of Ph+ ALL for whom no other tyrosine kinase inhibitor (TKI) therapy is allowed. The chemotherapy used in this study is FDA approved and commercially available for the treatment of ALL. It is considered investigational to use ponatinib in combination with chemotherapy to treat PH+ or BCR-ABL positive ALL.